The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First line combination of ribociclib and letrozole in patients (pts) with metastatic breast cancer (MBC): Focus on hepatic toxicity in the context of a real–world setting the Italian, multicenter Hermione–8 study.
 
Francesca Piazza
No Relationships to Disclose
 
Candida Bonelli
No Relationships to Disclose
 
Stefania Lui
No Relationships to Disclose
 
Camilla di Nunzio
No Relationships to Disclose
 
Elena Collova
No Relationships to Disclose
 
Elisabetta Bozzoli
No Relationships to Disclose
 
Patrizia Vici
Consulting or Advisory Role - Eisai; Lilly O.; Novartis; Pfizer
 
Vittorio Gebbia
No Relationships to Disclose
 
Maria Rosaria Valerio
No Relationships to Disclose
 
Fable Zustovich
No Relationships to Disclose
 
Paola Vanella
No Relationships to Disclose
 
Luigi Coltelli
No Relationships to Disclose
 
Mirco Pistelli
Consulting or Advisory Role - Gilead Sciences; Lilly O.; Novartis; Pfizer
Travel, Accommodations, Expenses - Gilead Sciences
 
Francesco Giotta
No Relationships to Disclose
 
Valter Torri
Consulting or Advisory Role - Merck
 
Marina Elena Cazzaniga
Honoraria - Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Novartis; pierre fabre; Roche
Research Funding - Eisai Europe (Inst); Lilly (Inst)